Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Niklas Ebert"'
Publikováno v:
Automotive and Engine Technology. 5:45-56
The effort and time demand for the calibration of electronic control systems for internal combustion engines on test benches is rising constantly for a number of years. This is mainly driven by new engines and powertrain technologies as well as by th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26839f74c39e2d166476cc8fd35ed076
https://doi.org/10.1007/s41104-020-00058-x
https://doi.org/10.1007/s41104-020-00058-x
Autor:
Matthias Saar, Tobias Stemler, Fadi Khreish, Mark Bartholomä, Florian Rosar, Samer Ezziddin, Niklas Ebert, Hendrik Bohnenberger, Stephan Maus, Martin Ries
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 47:721-728
Up to 30% of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) never respond or develop resistance to 177Lu-labeled PSMA-targeted radioligand monotherapy. Single-agent PSMA-target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::607750931f6317eccd69605619026a2e
https://doi.org/10.1007/s00259-019-04612-0
https://doi.org/10.1007/s00259-019-04612-0
Autor:
Matthias Saar, Niklas Ebert, Fadi Khreish, Samer Ezziddin, Stephan Maus, Tobias Stemler, Mark Bartholomä, Martin Ries, Florian Rosar, Hendrik Bohnenberger
Publikováno v:
58. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin.
Up to 30% of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) never respond or develop resistance to 177Lu-labeled PSMA-targeted radioligand monotherapy. Single-agent PSMA-target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1cf8baff8bb6795322f89c88b7ab89da
https://doi.org/10.1055/s-0040-1708132
https://doi.org/10.1055/s-0040-1708132